Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.
Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.
复制标题
DOI：
10.1586/14779072.2013.814830
复制
发表时间：
2013-08
影响因子：
2
通讯作者：
Sussman MA
中科院分区：
文献类型：
--
作者：
Siddiqi S;Sussman MA
严重心力衰竭患者的再生治疗提出了一系列具有挑战性的情况，包括加速心肌细胞和心脏祖细胞衰老的受损心肌环境。衰竭的心肌遭受收缩功能的恶化，再加上受损的再生潜力，使心脏失代偿。严重心力衰竭的有效再生细胞治疗需要打破这种恶性循环，这可以通过改变受损的肌细胞表型和祖细胞的再生来实现。本文综述了Pim-1激酶通过保护线粒体完整性、防止肥大和抑制细胞凋亡来改善心肌细胞质量，从而减轻慢性心力衰竭的潜力。此外，用Pim-1改造的心脏祖细胞具有增强的再生潜力，使Pim-1成为未来治疗严重心力衰竭的重要参与者。
Regenerative therapy in severe heart failure patients presents a challenging set of circumstances including a damaged myocardial environment that accelerates senescence in myocytes and cardiac progenitor cells. Failing myocardium suffers from deterioration of contractile function coupled with impaired regenerative potential that drives the heart toward decompensation. Efficacious regenerative cell therapy for severe heart failure requires disruption of this vicious circle that can be accomplished by alteration of the compromised myocyte phenotype and rejuvenation of progenitor cells. This review focuses upon potential for Pim-1 kinase to mitigate chronic heart failure by improving myocyte quality through preservation of mitochondrial integrity, prevention of hypertrophy and inhibition of apoptosis. In addition, cardiac progenitors engineered with Pim-1 possess enhanced regenerative potential, making Pim-1 an important player in future treatment of severe heart failure.